A Study to Assess the Effect of the Bio-K+ Probiotic Capsules (VL-BK-02) in Adults With Functional Constipation

Last updated: March 18, 2026
Sponsor: Vedic Lifesciences Pvt. Ltd.
Overall Status: Completed

Phase

N/A

Condition

Constipation

Treatment

Placebo (Microcrystalline Cellulose - 375 mg/capsule)

VL-BK-02 (25 billion CFU/Capsule)

Clinical Study ID

NCT06730594
KE/240401/BK+/FC V.2
  • Ages 18-60
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The present study is a randomized, placebo-controlled, double-blind, parallel-group clinical study designed to assess the effects of IP in individuals with Functional constipation as compared to a placebo. Approximately 205 individuals aged between 18 and 60 years will be screened.

Considering a screen failure of 20%, approximately 164 individuals will be randomized in a ratio of 1:1 to receive either the active or placebo. The study will have at least 126 completed participants i.e. 63 partcipants in each study arm after accounting for a dropout/withdrawal rate of 23% at the end of the study. The intervention duration for all the study participants will be 56 days with follow up of upto 84 days. The study flow chart given below indicates the time points at which safety and efficacy assessments will be conducted

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Individuals agreed to the signed and dated informed consent form.

  2. Male and female individuals of age between 18 to 60 years (both values included)

  3. Individuals who meet Rome IV diagnostic criteria for functional constipation asindicated by the criteria fulfilled for the last 3 months with symptoms onset atleast 6 months prior to diagnosis: i. Must include two or more of the following criteria:

  4. Fewer than three SBMs per week

  5. Straining during more than ¼ (25%) of defecations

  6. Lumpy or hard stools (Bristol Stool Form Scale 1-2) more than ¼ (25%) ofdefecations

  7. Sensation of incomplete evacuation more than ¼ (25%) of defecations

  8. Sensation of anorectal obstruction/ blockage more than ¼ (25%) of defecations

  9. Manual maneuvers to facilitate more than ¼ (25%) of defecations (e.g., digitalevacuation, support of the pelvic floor) ii. Loose stools are rarely presentwithout the use of laxatives iii. Insufficient criteria for irritable bowelsyndrome

  10. Individuals willing to comply with all study procedures and availability for theduration of the study as per the protocol.

  11. Individuals willing to maintain the same dietary and physical activity practicesthroughout the study period.

  12. Individuals with fewer than three CSBMs per week.

Exclusion

Exclusion Criteria:

  1. Individuals with well-known, organic cause of constipation (Polyps, hemorrhoids,etc.)

  2. Individuals with anorectal pathology

  3. Individuals with history of gastrointestinal surgery including appendisectomy.

  4. Individuals with any alarming symptoms (i.e. rectal bleeding, weight loss, jaundice)as judged by the Investigator.

  5. Individuals with concurrent chronic GI pathology (e.g. IBD, cystic fibrosis, shortgut, celiac disease, frequent diarrhea without laxative).

  6. Current pharmacological treatment related to constipation (e.g. prosecretory agents,antidepressants, antispasmodics, enterokinetic)

  7. Individuals consuming dietary treatment (e.g. synbiotics, herbal extracts, fibers)or taking other therapies for treating constipation (e.g. cognitive behaviortherapy, acupuncture, biofeedback, complementary and alternative Medicine) within 1month prior to screening.

  8. Use of antibiotics within 1 month prior to screening.

  9. Use of products containing probiotics, prebiotics, postbiotics, within 1 month priorto screening

  10. Opioids-induced constipation.

  11. Regular use of any drug or dietary supplement known to cause constipation (e.g.iron, opioids, sucralfate, misoprostol, 5-HT- antagonists, antacids with magnesium,calcium or aluminum, antidiarrheal medication, anticholinergic agents, calciumsupplements, calcium channel blockers, tricyclic antidepressants or NSAIDs) within 1month prior to screening.

  12. Immuno-compromised participants.

  13. Participants on immunosuppressive agents (e.g. heart or kidney transplant,chemotherapy agents, oral prednisolone)

  14. History of cancer .

  15. Individuals with known history of diabetes mellitus and are on medication for thesame.

  16. Individuals suffereing from Diabetic gastroparesis.

  17. History of uncontrolled hypertension and/or systolic blood pressure ≥ 140 mmHgand/or diastolic blood pressure ≥ 90 mmHg.

  18. Individuals with impaired thyroid function reported by TSH less than 0.4 mIU/L andmore than 5 mIU/L will be excluded. However, individuals on a stable dose ofmedication for past 6 months and within the aforementioned range, can be considered.

  19. Psychiatric or behavioral disorders as judged by the Investigator

  20. Individuals with known food allergy.

  21. Individuals with eating disorders (e.g., anorexia, bulimia)

  22. Pregnancy or lactation

  23. Known allergic reactions to any components of the probiotics or placebo.

  24. Individuals participating in other interventional study within 90 days prior toscreening.

  25. Individuals with a history of alcohol or drug abuse based on medical history,physical examination, or the Investigators clinical judgment.

  26. Current Smokers.

  27. Individuals with more than 14 SBMs per week.

Study Design

Total Participants: 168
Treatment Group(s): 2
Primary Treatment: Placebo (Microcrystalline Cellulose - 375 mg/capsule)
Phase:
Study Start date:
January 25, 2025
Estimated Completion Date:
March 14, 2026

Connect with a study center

  • Anand Multispeciality Hospital

    Vadodara, Gujarat 390016
    India

    Site Not Available

  • HCG Hospitals

    Ahmedabad, Gujrata 380006,
    India

    Site Not Available

  • Jan Kalyan Multispeciality Hospital

    Kalyān, Maharashtra 421 306
    India

    Site Not Available

  • Signus Hospital

    Nashik, Maharashtra 422010
    India

    Site Not Available

  • AK Superspeciality Clinic

    Pune, Maharashtra 411014
    India

    Site Not Available

  • Care Multispecialty Hospital

    Pune, Maharashtra 412207
    India

    Site Not Available

  • Gastrohub Hospital

    Pune, Maharashtra 411027
    India

    Site Not Available

  • Lifeline multispecialty Hospital

    Pune, Maharashtra 412101
    India

    Site Not Available

  • Krishna Hospital

    Varanasi, Uttar Pradesh 221005
    India

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.